Search

Your search keyword '"Umezu, Tomokazu"' showing total 44 results
Start Over Author "Umezu, Tomokazu"
44 results on '"Umezu, Tomokazu"'

11. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary

Author

Umezu, Tomokazu, Shibata, Kiyosumi, Kajiyama, Hiroaki, Yamamoto, Eiko, Nawa, Akihiro, and Kikkawa, Fumitaka

Subjects
Ovarian cancer -- Patient outcomes, Ovarian cancer -- Research, Adenocarcinoma -- Patient outcomes, Adenocarcinoma -- Research, Proteoglycans -- Measurement, Proteoglycans -- Physiological aspects, Proteoglycans -- Research, Diagnostic immunohistochemistry -- Usage, Diagnostic immunohistochemistry -- Research, Cell proliferation -- Analysis, Health
Published
2010

20. STRONG ANTIBODY REACTION AGAINST GLYCOSPHINGOLIPIDS INJECTED IN LIPOSOMEEMBEDDED FORMS IN β3GN-T5 KNOCKOUT MICE

Author

FAN, XIAOYAN, KONDO, YUJI, TOKUDA, NORIYO, OHMI, YUHSUKE, ANDO, REIKO, UMEZU, TOMOKAZU, ZHANG, QING, FURUKAWA, KEIKO, SHIBATA, KIYOSUMI, TOGAYACHI, AKIRA, NARIMATSU, HISASHI, OKAJIMA, TETSUYA, KIKKAWA, KOJI, and FURUKAWA, KOICHI

Subjects
carbohydrates (lipids), Liposome, Knockout, Gangliosides, lipids (amino acids, peptides, and proteins), Immunization, Glycolipids, Antibody
Abstract

It is known that mutant mice of the β-1,3-N-acetylglucosaminyltransferase gene (β3Gn-T5) respond well to T-cell dependent and independent antigens. Here, we examined the effectiveness of anti-ganglioside antibody generation by immunization of β3Gn-T5 mutant mice with liposome-embedded glycosphingolipids such as GD1a and GT1b. Consequently, the mutant mice showed a more efficient generation of anti-GD1a or anti-GT1b antibodies than wild-type mice in an enzyme-linked immunosorbent assay using sera during immunization. Thus, the β3Gn-T5 deficient mutant mice proved more responsive than wild-type mice to not only protein antigens, but also to carbohydrates in glycolipids. Furthermore, about 50% of monoclonal antibodies generated using splenocytes of the immunized mutant mice were of the IgG class. Besides general high responsiveness to proteins and glycolipids, it could be expected that the mutant mice of β3Gn-T5 would be useful in the generation of monoclonal antibodies towards lacto-/neolacto-series glycolipids, since these mutants lack lacto-/neolacto-series glycolipids. In fact, they showed a good serum response in immuno-fluorescence assay with cultured living cells when immunized by glycolipids extracted from ovarian cancer cell lines. These results suggested that β3Gn-T5 mutant mice are useful for the generation of anti-glycolipid antigens with lacto-/neolacto-core structures expressed in cancer cells.

Published
2011

21. LONG-TERM OUTCOME AND PROGNOSTIC FACTORS FOR YOLK SAC TUMOR OF THE OVARY

Author

UMEZU, TOMOKAZU, KAJIYAMA, HIROAKI, TERAUCHI, MIKIO, SHIBATA, KIYOSUMI, INO, KAZUHIKO, NAWA, AKIHIRO, and KIKKAWA, FUMITAKA

Subjects
Prognostic factor, Yolk sac tumor, Survival
Abstract

Yolk sac tumors of the ovary (YST) are rare and highly malignant tumors occurring in children and young adults. Because of its rarity, YST prognostic factors remain unclear. Our purpose was to evaluate the prognostic factors in YST. We performed a retrospective review of 36 patients with pure YST from 1986 to 2006. The 5-year overall survival and progression-free survival were 66.6% and 68.8%, respectively. Patients with stage I–II disease had a more favorable prognosis than those with stage III–IV (p < 0.05). Those with an ascites volume of less than 100 ml or a residual tumor measuring less than 1 cm had improved to a relatively good prognosis. Neither serum AFP level nor age had any significant correlation with the prognosis in this study. In conclusion, the FIGO (International Federation of Gynecology and Obstetrics) stage, ascites volume and residual tumor size tended to affect the prognosis of YST.

Published
2008

24. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?

Author

Kajiyama, Hiroaki, primary, Mizuno, Mika, additional, Shibata, Kiyosumi, additional, Umezu, Tomokazu, additional, Suzuki, Shiro, additional, Yamamoto, Eiko, additional, Mitsui, Hiroko, additional, Sekiya, Ryuichiro, additional, Niimi, Kaoru, additional, Kawai, Michiyasu, additional, Nagasaka, Tetsuro, additional, and Kikkawa, Fumitaka, additional

Published
2014
Full Text
View/download PDF

25. Opioid needs of terminally ill patients with gynecologic malignancies

Author

Utsumi, Fumi, primary, Kajiyama, Hiroaki, additional, Sakata, Jun, additional, Higashi, Makiko, additional, Niimi, Kaoru, additional, Sekiya, Ryuichiro, additional, Mitsui, Hiroko, additional, Suzuki, Shiro, additional, Umezu, Tomokazu, additional, Mizuno, Mika, additional, Yamamoto, Eiko, additional, Shibata, Kiyosumi, additional, and Kikkawa, Fumitaka, additional

Published
2014
Full Text
View/download PDF

26. Is There Any Association between Where Patients Spend the End of Life and Survival after Anticancer Treatment for Gynecologic Malignancy?

Author

Kajiyama, Hiroaki, primary, Utsumi, Fumi, additional, Higashi, Makiko, additional, Sakata, Jun, additional, Sekiya, Ryuichiro, additional, Mizuno, Mika, additional, Umezu, Tomokazu, additional, Suzuki, Shiro, additional, Yamamoto, Eiko, additional, Mitsui, Hiroko, additional, Niimi, Kaoru, additional, Shibata, Kiyosumi, additional, and Kikkawa, Fumitaka, additional

Published
2014
Full Text
View/download PDF

27. Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology

Author

Kajiyama, Hiroaki, primary, Shibata, Kiyosumi, additional, Mizuno, Mika, additional, Umezu, Tomokazu, additional, Suzuki, Shiro, additional, Sekiya, Ryuichiro, additional, Niimi, Kaoru, additional, Mitsui, Hiroko, additional, Yamamoto, Eiko, additional, Kawai, Michiyasu, additional, Nagasaka, Tetsuro, additional, and Kikkawa, Fumitaka, additional

Published
2014
Full Text
View/download PDF

29. A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age

Author

Kajiyama, Hiroaki, primary, Mizuno, Mika, additional, Shibata, Kiyosumi, additional, Umezu, Tomokazu, additional, Suzuki, Shiro, additional, Yamamoto, Eiko, additional, Mitsui, Hiroko, additional, Sekiya, Ryuichiro, additional, Niimi, Kaoru, additional, Kawai, Michiyasu, additional, Nagasaka, Tetsuro, additional, and Kikkawa, Fumitaka, additional

Published
2013
Full Text
View/download PDF

36. Three-dimensional CT Angiography Is Useful for Diagnosis of Postabortion Uterine Hemorrhage: 3 Case Reports and Review of the Literature

Author

Umezu, Tomokazu, primary, Iwase, Akira, additional, Ota, Toyohiro, additional, Suzuki, Kojiro, additional, Nakagawa, Akiko, additional, Nakahara, Tatsuo, additional, Takikawa, Sachiko, additional, Kobayashi, Hiroharu, additional, Manabe, Shuichi, additional, Suzuki, Kyosuke, additional, Goto, Maki, additional, and Kikkawa, Fumitaka, additional

Published
2010
Full Text
View/download PDF

40. Taxol Resistance Among the Different Histological Subtypes of Ovarian Cancer May Be Associated With the Expression of Class III -Tubulin

Author

Umezu, Tomokazu, Shibata, Kiyosumi, Kajiyama, Hiroaki, Terauchi, Mikio, Ino, Kazuhiko, Nawa, Akihiro, and Kikkawa, Fumitaka

Abstract

The prognostic significance of histology has been well established in epithelial ovarian cancer (EOC). Clear cell and mucinous histologies are especially generally accepted to result in an adverse outcome because of their poor chemotherapy response. Previous reports suggested that class III -tubulin induced taxol resistance in association with a reduced effect on microtubule dynamic instability. Thus, this study aimed to evaluate class III -tubulin expression and examine whether the protein level of class III -tubulin was correlated with the histological difference in chemosensitivity. Class III -tubulin expression in EOC tissues (n = 80) was immunohistochemically scored into 4 groups (−, ±, +, ++). High-level (+, ++) class III -tubulin expression was detected in 30 of 35 clear cell carcinomas, in 8 of 10 mucinous carcinomas, 5 of 11 endometrioid carcinomas, and 5 of 24 serous carcinomas. Nineteen patients were evaluable for response. In 5 responders, high-level class III -tubulin expression was not detected. On the other hand, it was detected in 10 of 14 nonresponders. In some ovarian cancer cell lines, we evaluated class III -tubulin expression by Western blot analysis. Class III -tubulin expression in nonserous carcinoma tended to be higher than that in serous carcinoma. Taxol-resistant SKOV cells showed high-level class III -tubulin expression compared with wild-type SKOV cells. Taxol sensitivity differing among histological subtypes in EOC is associated with the expression of class III -tubulin.

Published
2008
Full Text
View/download PDF

41. Plasma Exchange in Postpartum Hemorrhage (PPH)-Associated Thrombotic Microangiopathy (TMA): A Case Report.

Author

Okawa A, Yoshihara M, Osafune A, Umezu T, and Kajiyama H

Abstract

Thrombotic microangiopathy (TMA) is a rare yet potentially life-threatening condition. The diagnosis is difficult as there are other conditions presenting with features akin to TMA during the peripartum period such as eclampsia, preeclampsia, hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome, and antiphospholipid syndrome. A 28-year-old woman with no significant past medical history developed TMA following a massive hemorrhage after an emergency cesarean section at 41 weeks of gestation. This case was finally diagnosed as postpartum hemorrhage (PPH)-associated TMA. The patient fully recovered after plasma exchange therapy. We posit the value of accumulating case reports, given that the documentation on the efficacy of plasma exchange in PPH-associated TMA is limited., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Okawa et al.)

Published
2024
Full Text
View/download PDF

42. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?

Author

Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Niimi K, Kawai M, Nagasaka T, and Kikkawa F

Subjects
Adenocarcinoma, Clear Cell therapy, Adenocarcinoma, Mucinous therapy, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Ovarian Epithelial, Chemotherapy, Adjuvant, Female, Humans, Hysterectomy, Lymph Node Excision, Middle Aged, Neoplasm Staging, Neoplasms, Glandular and Epithelial therapy, Ovarian Neoplasms therapy, Ovariectomy, Prognosis, Salpingectomy, Survival Rate, Young Adult, Adenocarcinoma, Clear Cell pathology, Adenocarcinoma, Mucinous pathology, Neoplasm Recurrence, Local pathology, Neoplasms, Glandular and Epithelial pathology, Ovarian Neoplasms pathology
Abstract

Objectives: This study was conducted to estimate the oncologic outcome of stage I epithelial ovarian carcinoma (EOC) patients after recurrence., Study Design: After central pathological review and searching of the medical records of multi-institutions, a total of 103 relapsed patients with stage I EOC were analyzed. The major endpoint was postrecurrence survival (PRS)., Results: The median follow-up for surviving patients was 57.5 (5.7-242.0) months. The median age was 52 (14-89). Among the patients, 19 (18.4%) had FIGO IA disease, and 4 (3.9%) and 80 (77.7%) had IB and IC disease, respectively. Regarding the histological type, the clear-cell type was the most frequently observed (N=42: 40.8%). The 3/5-year overall and PRS rates of all patients were 63.7/47.9 and 38.2/24.0%, respectively. The 5-year PRS rates of patients with serous, endometrioid, clear-cell, and mucinous tumors were 44.9, 35.0, 19.8, and 0%, respectively. On stratifying by the histological type, the overall and postrecurrence survival rates of patients with the mucinous/clear-cell types were significantly poorer than in those with the non-mucinous/clear-cell types (OS: P=0.0253, PRS: P=0.0016). In multivariate analyses, the FIGO stage (IA/IB vs. IC) and histological type (clear-cell/mucinous vs. non- clear-cell/mucinous) retained their significance as prognostic factors of a poorer PRS {stage IC (vs., Ia/b) Hr: 2.176 (95% CI: 1.059-4.470), P=0.0343: clear-cell/mucinous (vs. non- clear-cell/mucinous): HR: 2.486(95% CI: 1.416-4.364), P=0.0015)., Conclusions: Even if at stage I, once patients with a mucinous/clear-cell histology experience recurrence, subsequent survival is extremely poor., (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)

Published
2014
Full Text
View/download PDF

43. Strong antibody reaction against glycosphingolipids injected in liposome-embedded forms in beta3GN-T5 knockout mice.

Author

Fan X, Kondo Y, Tokuda N, Ohmi Y, Ando R, Umezu T, Zhang Q, Furukawa K, Shibata K, Togayachi A, Narimatsu H, Okajima T, Kikkawa K, and Furukawa K

Subjects
Animals, Cell Line, Tumor, Female, Humans, Immunization, Immunoglobulin G biosynthesis, Mice, Mice, Inbred C57BL, N-Acetylglucosaminyltransferases genetics, Antibodies, Monoclonal biosynthesis, Glycosphingolipids immunology, N-Acetylglucosaminyltransferases physiology
Abstract

It is known that mutant mice of the beta-1,3-N-acetylglucosaminyltransferase gene (beta3Gn-T5) respond well to T-cell dependent and independent antigens. Here, we examined the effectiveness of anti-ganglioside antibody generation by immunization of beta3Gn-T5 mutant mice with liposome-embedded glycosphingolipids such as GD1a and GT1b. Consequently, the mutant mice showed a more efficient generation of anti-GD1a or anti-GT1b antibodies than wild-type mice in an enzyme-linked immunosorbent assay using sera during immunization. Thus, the beta3Gn-T5 deficient mutant mice proved more responsive than wild-type mice to not only protein antigens, but also to carbohydrates in glycolipids. Furthermore, about 50% of monoclonal antibodies generated using splenocytes of the immunized mutant mice were of the IgG class. Besides general high responsiveness to proteins and glycolipids, it could be expected that the mutant mice of beta3Gn-T5 would be useful in the generation of monoclonal antibodies towards lacto-/neolacto-series glycolipids, since these mutants lack lacto-/neolacto-series glycolipids. In fact, they showed a good serum response in immuno-fluorescence assay with cultured living cells when immunized by glycolipids extracted from ovarian cancer cell lines. These results suggested that beta3Gn-T5 mutant mice are useful for the generation of anti-glycolipid antigens with lacto-/neolacto-core structures expressed in cancer cells.

Published
2011

44. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.

Author

Umezu T, Shibata K, Kajiyama H, Terauchi M, Ino K, Nawa A, and Kikkawa F

Subjects
Adenocarcinoma, Clear Cell drug therapy, Adenocarcinoma, Clear Cell metabolism, Adult, Aged, Carcinoma, Endometrioid drug therapy, Carcinoma, Endometrioid metabolism, Cell Line, Tumor, Female, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Neoplasms, Cystic, Mucinous, and Serous drug therapy, Neoplasms, Cystic, Mucinous, and Serous metabolism, Tubulin drug effects, Tubulin genetics, Antineoplastic Agents, Phytogenic pharmacology, Drug Resistance, Neoplasm, Ovarian Neoplasms drug therapy, Ovarian Neoplasms metabolism, Paclitaxel pharmacology, Tubulin metabolism
Abstract

The prognostic significance of histology has been well established in epithelial ovarian cancer (EOC). Clear cell and mucinous histologies are especially generally accepted to result in an adverse outcome because of their poor chemotherapy response. Previous reports suggested that class III beta-tubulin induced taxol resistance in association with a reduced effect on microtubule dynamic instability. Thus, this study aimed to evaluate class III beta-tubulin expression and examine whether the protein level of class III beta-tubulin was correlated with the histological difference in chemosensitivity. Class III beta-tubulin expression in EOC tissues (n = 80) was immunohistochemically scored into 4 groups (-, +/-, +, ++). High-level (+, ++) class III beta-tubulin expression was detected in 30 of 35 clear cell carcinomas, in 8 of 10 mucinous carcinomas, 5 of 11 endometrioid carcinomas, and 5 of 24 serous carcinomas. Nineteen patients were evaluable for response. In 5 responders, high-level class III beta-tubulin expression was not detected. On the other hand, it was detected in 10 of 14 nonresponders. In some ovarian cancer cell lines, we evaluated class III beta-tubulin expression by Western blot analysis. Class III beta-tubulin expression in nonserous carcinoma tended to be higher than that in serous carcinoma. Taxol-resistant SKOV cells showed high-level class III beta-tubulin expression compared with wild-type SKOV cells. Taxol sensitivity differing among histological subtypes in EOC is associated with the expression of class III beta-tubulin.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results